AzTrials
AzTrials

Weight LossEX-RWL-LymphocNCT07567937

Effects of Exercise and Short Term Rapid Weight Loss on Whole Blood Cells and Lymphocyte Subsets in Highly Trained National Level Wrestlers

A study testing Exercise and Rapid Weight Loss in people with Weight Loss and Exercise, run by Ankara Yildirim Beyazıt University at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Wrestling is a weight-classified sport in which athletes frequently apply rapid weight loss (RWL) strategies prior to competition. While the performance-related consequences of RWL have been widely investigated, its combined effects with exercise on hematological parameters and immune cell profiles remain… Read more about this study

Who is it for?
Ages 18 to 35 years, men onlyHealthy volunteers can take part
Conditions the study is for
Weight Loss, Exercise
What is being tested?
Exercise and Rapid Weight Loss
Could I receive a placebo?
No, everyone receives an active treatment
How many people
9 participants
Where
1 siteTurkey (Türkiye)
Study dates
21 Jun 2021to 10 Oct 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 35 years
  • Men only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Being between 18 and 35 years of age
  • Being clinically healthy
  • Actively competing in wrestling
  • Having regular training experience
  • No history of chronic disease
  • No musculoskeletal injury that could affect performance
  • Not using any medication or nutritional supplements that could influence hematological or biochemical parameters during the study period
  • Willing to volunteer and provide written informed consent

Who cannot join

  • Having any chronic disease (e.g., cardiovascular, metabolic, respiratory, or neurological disorders)
  • Having a recent musculoskeletal injury that could affect exercise performance
  • Using medications, ergogenic aids, or nutritional supplements that might influence hematological or biochemical parameters
  • Having a history of smoking or alcohol abuse
  • Failing to complete the testing procedures and training protocol required for the study
  • Not providing written informed consent
  • Withdrawing voluntarily during the study period

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Ankara Yildirim Beyazit University Sports Sciences Laboratory

    Ankara, Ankara, 06000

Other trials in Turkey (Türkiye)

About this study

Official title: Effects of Exercise and Short-Term Rapid Weight Loss on Whole Blood Cells and Lymphocyte Subsets in Highly Trained National-Level Wrestlers: A Two-Phase Repeated-Measures Study

Wrestling is a weight-classified sport in which athletes frequently apply rapid weight loss (RWL) strategies prior to competition. While the performance-related consequences of RWL have been widely investigated, its combined effects with exercise on hematological parameters and immune cell profiles remain insufficiently understood. Therefore, this study aims to examine the effects of short-term weight loss and exercise on whole blood cell parameters and lymphocyte subsets in elite wrestlers.

Nine elite male wrestlers actively competing in the senior category (mean age: 22.90 ± 5.15 years; mean height: 1.75 m) voluntarily participated in this study. Athletes will achieve an average body mass reduction of 4.3% over a five-day period. Venous blood samples will be collected at 09:30 a.m. in a fasted state during two experimental phases: (1) Exercise-only phase, with blood sampling before and after exercise (BRWL1 and BRWL2); (2) Exercise plus weight loss phase, following the five-day weight loss period, with blood sampling before and after exercise (ARWL1 and ARWL2). Complete blood count parameters will be analyzed using an automated hematology analyzer, while lymphocyte subsets (CD3+, CD4+, CD8+, CD19+, CD16/56+) will be assessed by flow cytometry. Statistical analyses will be performed with a significance level set at p < 0.05.

Read the detailed description

See brief summary for study protocol details

Being tested
Exercise, Rapid Weight Loss
Keywords
Complete Blood Count, Exercise, Flow Cytometry, Lymphocyte Subsets, Immune System, Rapid Weight Loss
Medical subject headings
Weight Loss, Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ExerciseOther

    Also called Behavioral

    Standardized wrestling exercise session; pre- and post-exercise venous blood collected

  • Rapid Weight LossOther

    5-day rapid weight loss protocol achieving average 4.3% body mass reduction

Study groups in NCT07567937
Study groupRoleWhat they receive
ExerciseOtherParticipants performed a standardized wrestling exercise session on the first day of testing. Venous blood samples were collected pre- and post-exercise (pre-exercise: BRWL1; post-exercise: BRWL2) to evaluate hematological and lymphocyte subset responses.
Receives: Other: Exercise
Exercise + Rapid Weight LossOtherParticipants underwent a 5-day rapid weight loss protocol prior to the exercise session, achieving an average body mass reduction of 4.3%. On the fifth day, the same standardized exercise protocol as Group 1 was performed, and pre- and post-exercise blood samples were collected (pre-exercise: ARWL1; post-exercise: ARWL2) to evaluate hematological and lymphocyte subset responses.
Receives: Other: Exercise; Other: Rapid Weight Loss

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Leukocyte Count

    Change in total white blood cell (WBC) count measured from pre- to post-exercise

    Measured: Pre- and post-exercise (Day 1 for Exercise Only group; Day 5 for Exercise + Rapid Weight Loss group)

  2. Change in Lymphocyte Percentage

    Change in percentage of lymphocytes relative to total WBC count, measured from pre- to post-exercise.

    Measured: Pre- and post-exercise (Day 1 for Exercise Only group; Day 5 for Exercise + Rapid Weight Loss group)

  3. Change in CD3+ T Cell Count

    Change in absolute count of CD3+ T lymphocytes measured from pre- to post-exercise.

    Measured: Pre- and post-exercise (Day 1 for Exercise Only group; Day 5 for Exercise + Rapid Weight Loss group)

  4. Change in CD4+ T Cell Count

    Change in absolute count of CD4+ helper T lymphocytes measured from pre- to post-exercise.

    Measured: Pre- and post-exercise (Day 1 for Exercise Only group; Day 5 for Exercise + Rapid Weight Loss group)

  5. Change in CD8+ T Cell Count

    Change in absolute count of CD8+ cytotoxic T lymphocytes measured from pre- to post-exercise.

    Measured: Pre- and post-exercise (Day 1 for Exercise Only group; Day 5 for Exercise + Rapid Weight Loss group)

  6. Change in CD19+ B Cell Count

    Change in absolute count of CD19+ B lymphocytes measured from pre- to post-exercise.

    Measured: Pre- and post-exercise (Day 1 for Exercise Only group; Day 5 for Exercise + Rapid Weight Loss group)

  7. Change in CD16/56+ NK Cell Count

    Change in absolute count of CD16/56+ natural killer (NK) cells measured from pre- to post-exercise.

    Measured: Pre- and post-exercise (Day 1 for Exercise Only group; Day 5 for Exercise + Rapid Weight Loss group)

Secondary outcomes (1)
  1. Change in Creatine Kinase and Lactic Acid Levels

    Serum creatine kinase (CK) and lactic acid (LA) levels measured to assess anaerobic performance and muscle damage.

    Measured: Pre-exercise and post-exercise (Day 1 for Exercise Only group; Day 5 for Exercise + Rapid Weight Loss group)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 May 2026
  2. Study start21 Jun 2021
  3. Primary completion3 Apr 2022
  4. Study completion10 Oct 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Non-randomised
Intervention model
Sequential
Masking
None (open label)
Enrolment
9 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07567937
Sponsor's protocol ID
2280
Acronym
EX-RWL-Lymphoc
Status last verified
May 2026
First submitted
22 Apr 2026
Last updated
15 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Exercise and Rapid Weight Loss in people with Weight Loss and Exercise, run by Ankara Yildirim Beyazıt University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Leukocyte Count (time frame: Pre- and post-exercise (Day 1 for Exercise Only group; Day 5 for Exercise + Rapid Weight Loss group)). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in